Advertisement


Toni K. Choueiri, MD, on Renal Cell Carcinoma: Follow-up Data on Pembrolizumab

2022 ASCO Genitourinary Cancers Symposium

Advertisement

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses a 30-month follow-up of results from the KEYNOTE-564 trial, which further support the use of adjuvant pembrolizumab when treating patients with renal cell carcinoma at intermediate-high or high risk of recurrence, or with an M1 NED (no evidence of disease) status after nephrectomy. The data show a disease-free survival benefit vs placebo (Abstract 290).



Related Videos

Bladder Cancer

Massimo Di Maio, MD, on Urothelial Cancer: Data on Niraparib and Best Supportive Care as Maintenance Therapy

Massimo Di Maio, MD, of the University of Turin, discusses the Meet-URO12 study, which showed that maintenance niraparib plus best supportive care (BSC) did not prolong progression-free survival, compared with BSC alone, among patients with urothelial cancer that did not progress after first-line platinum-based chemotherapy.

Solid Tumors
Immunotherapy

Hielke-Martijn de Vries, MD, on Penile Cancer: New Data on Atezolizumab and Radiotherapy

Hielke-Martijn de Vries, MD, of the Netherlands Cancer Institute, discusses phase II findings on the use of atezolizumab with or without radiotherapy for patients with advanced squamous cell carcinoma of the penis. The study was designed to address the poor prognosis for this disease by exploring whether a protracted schedule of radiotherapy for locoregional disease, in combination with immunotherapy, could improve outcomes (Abstract 3).

Prostate Cancer

Neil E. Fleshner, MD, MPH, on High-Risk Prostate Cancer: New Data on Abiraterone and Cabazitaxel

Neil E. Fleshner, MD, MPH, of the Princess Margaret Cancer Centre, discusses phase II results from the ACDC-RP trial, which indicate a significant tumor response to neoadjuvant abiraterone acetate plus prednisone and leuprolide, with or without cabazitaxel, in patients with high-risk prostate cancer. Those who exhibited either a complete response or minimal residual disease experienced higher rates of progression-free survival. According to Dr. Fleshner, genomic efforts are underway to determine predictors of response.

Bladder Cancer
Immunotherapy

Jonathan E. Rosenberg, MD, on Urothelial Cancer: New Conclusions About Durvalumab Plus Olaparib

Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discusses phase II findings from the BAYOU trial, which studied durvalumab in combination with olaparib for first-line treatment of platinum-ineligible patients with unresectable, stage IV urothelial carcinoma. Because secondary analyses indicated a potential progression-free survival benefit with this combination, there may be a role for PARP inhibitors in the treatment of advanced disease with homologous recombination repair mutation (Abstract 437).

Bladder Cancer

Simon J. Crabb, PhD, MBBS, on Urothelial Carcinoma: Switch Maintenance Therapy With Rucaparib Following Chemotherapy

Simon J. Crabb, PhD, MBBS, of the Southampton Experimental Cancer Medicine Centre, discusses data from the ATLANTIS trial, in which the authors hypothesized that switch maintenance therapy with the PARP inhibitor rucaparib, in patients who have derived clinical benefit from first-line chemotherapy, may improve outcomes for those with metastatic urothelial carcinoma that harbored a composite biomarker for DNA repair deficiency (Abstract 436).

Advertisement

Advertisement




Advertisement